Health Care | Health Care Equipment & Services | Health Care Equipment & Supplies | Health Care Equipment
NASDAQ | Common Stock
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally.
The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.
It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina.
In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions.
Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves.
It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors.
The company was incorporated in 2009 and is headquartered in Santa Clara, California.
As of May 31, 2024, Shockwave Medical, Inc. operates as a subsidiary of Johnson & Johnson.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 24 | 1.44 Increased by +39.81% | 0.98 Increased by +46.94% |
| Feb 15, 24 | 1.16 Decreased by -1.69% | 0.89 Increased by +30.34% |
| Nov 6, 23 | 0.92 Increased by 0.00% | 0.79 Increased by +16.46% |
| Aug 7, 23 | 0.76 Increased by +11.76% | 0.86 Decreased by -11.63% |
| May 8, 23 | 1.03 Increased by +164.10% | 0.81 Increased by +27.16% |
| Feb 16, 23 | 1.18 Increased by +247.06% | 1.01 Increased by +16.83% |
| Nov 7, 22 | 0.92 Increased by +1.74 K% | 0.67 Increased by +37.31% |
| Aug 8, 22 | 0.68 Increased by +6.90 K% | 0.44 Increased by +54.55% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 218.81 M Increased by +35.85% | 55.35 M Increased by +41.46% | Increased by +25.29% Increased by +4.13% |
| Dec 31, 23 | 202.98 M Increased by +40.93% | 44.30 M Decreased by -68.56% | Increased by +21.83% Decreased by -77.69% |
| Sep 30, 23 | 186.02 M Increased by +41.64% | 34.99 M Decreased by -0.05% | Increased by +18.81% Decreased by -29.43% |
| Jun 30, 23 | 180.16 M Increased by +49.21% | 28.86 M Increased by +12.91% | Increased by +16.02% Decreased by -24.33% |
| Mar 31, 23 | 161.07 M Increased by +72.02% | 39.13 M Increased by +169.44% | Increased by +24.29% Increased by +56.63% |
| Dec 31, 22 | 144.03 M Increased by +71.09% | 140.91 M Increased by +988.79% | Increased by +97.84% Increased by +536.40% |
| Sep 30, 22 | 131.33 M Increased by +101.57% | 35.00 M Increased by +1.70 K% | Increased by +26.65% Increased by +791.46% |
| Jun 30, 22 | 120.75 M Increased by +115.97% | 25.56 M Increased by +6.11 K% | Increased by +21.17% Increased by +2.88 K% |